

Eugene de Juan, Jr., MD

Jean Kelly Stock Distinguished Professor, University of California, San Francisco
Founder and Managing Partner, ForSight Labs, USA

Dr. Eugene de Juan, Jr. is a pioneering surgeon, prolific inventor, and visionary entrepreneur in the field of ophthalmology. As Founder of ForSight Labs, he plays a critical role in identifying and advancing transformative ophthalmic technologies, serving as both inventor and advisor for numerous early-stage ventures. He also holds the Jean Kelly Stock Distinguished Chair in Ophthalmology at the University of California, San Francisco (UCSF), where he continues to treat patients, perform surgery, and mentor the next generation of physician-scientists.

With more than 250 issued patents and over 250 peer-reviewed publications, Dr. de Juan's work has significantly shaped the field of ophthalmic innovation. He has contributed to the development of over 100 products and founded over 20 companies, including Second Sight, InnoRx (acquired by Surmodics), ForSight Visions 1-7 and Transcend Medical—the first spinout from ForSight Labs. He has started 4 companies to treat glaucoma. The most recent is Perceive Pharma, which is focused on next generation medical treatment for glaucoma.

Before relocating to San Francisco, Dr. de Juan held several academic and leadership positions. He was Professor of Ophthalmology at the University of Southern California. At Johns Hopkins University's Wilmer Eye Institute, he served as the Joseph E. Green Professor of Ophthalmology, Co-Director of the Vitreoretinal Service, and Director of the Microsurgery Advanced Design Laboratory (MADLAB). He also served on the medical staff of the Duke Eye Center with joint appointments in ophthalmology and cell biology.

Dr. de Juan earned his MD from the University of South Alabama College of Medicine, where he also completed his internship. He trained in ophthalmology at the Wilmer Eye Institute and completed a vitreoretinal surgery fellowship at Duke University. His career continues to bridge clinical excellence, academic leadership, and groundbreaking innovation.